Success Story: EB1A Approved! Our Firm Assisted a Biotechnology Expert in Securing Success without an RFE
Client’s Testimonial:
"It's been a pleasure to work with you. Besides the I-140 success, I've always been impressed by your timely, professional, and informative communication.”
On March 17th, 2026, we received an EB-1A (Alien of Extraordinary Ability) approval for a researcher in the Field of Biotechnologies (Approval Notice).
General Field: Biotechnologies
Position at the Time of Case Filing: Postdoctoral Associate
Country of Origin: China
State of Residence at the Time of Filing: North Carolina
Approval Notice Date: March 17th, 2026
Processing Time: 17 months, 21 days
Case Summary:
Our firm is pleased to share the successful approval of an EB-1A petition for a postdoctoral associate in biotechnology. The client, who holds a Ph.D. in genetics, development, and disease, approached our firm seeking support in securing permanent residency through the EB-1A (Alien of Extraordinary Ability) category.
After a thorough review of the expert's achievements and impact, our team prepared a compelling petition that resulted in the approval of the I-140 EB-1A filing. This approval underscores the client's extraordinary influence in genome and epigenome engineering research and its wide-ranging implications for human health.
Accomplishments and Expertise
The client has established a strong reputation as a leading researcher in biotechnology, with particular expertise in genome and epigenome engineering, multi-omics, bioinformatics, and engineering of viral delivery systems. Their contributions have been especially influential in developing foundational methods for studying how genetic elements regulate gene expression at the single-cell level, work that is now widely referenced by researchers across the globe. In support of the EB-1A petition, our firm highlighted several objective achievements, including:
- 9 peer-reviewed journal articles (1 first-authored, 2 co-first-authored)
- 551 citations with multiple papers ranked among the most highly cited
- At least 10 completed peer reviews for top-ranked journals
The client's research has also been supported by an impressive roster of prestigious funding organizations, including the Cancer Prevention and Research Institute of Texas, the American Heart Association, the National Institutes of Health, the Department of Defense, the Burroughs Wellcome Fund, the March of Dimes Foundation, the Welch Foundation, and the Texas Alzheimer's Research and Care Consortium.
Letters of Recommendation
To further support the petition, our firm obtained four letters of recommendation from highly regarded experts in biotechnologies and genomics research. One independent expert noted:
"[Client]’s prowess in human genomics and disease research, along with his extensive service as a peer reviewer, situates him as a leader in the field and establishes his inherent value to the United States."
EB-1A Approval and Outlook
The EB-1A petition was approved in just over 17 months without an RFE. The client's continued work in genome engineering and disease research promises to advance therapeutic development for conditions including cancer, schizophrenia, Parkinson's disease, and Alzheimer's disease, areas of strong and growing national importance in the United States. Our firm is honored to have represented the client in this successful EB-1A petition and looks forward to seeing the continued contributions the client will make to advancing biotechnology research and its transformative applications in human medicine.